ProPhase Labs, Inc. Goodwill
ProPhase Labs, Inc. (PRPH) had Goodwill of $3.97 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:Goodwill · last filed 2026-08-19
- 2026-06-30: Goodwill $3.97M.
- 2026-03-31: Goodwill $3.97M.
- 2025-12-31: Goodwill $3.97M.
- 2025-09-30: Goodwill $3.97M.
| Period end | Goodwill | Goodwill as first filed |
|---|---|---|
| 2026-06-30 | $3.97M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $3.97M 10-Q/A · filed 2026-07-09 | |
| 2025-12-31 | $3.97M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $3.97M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $5.23M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $5.23M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $5.23M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $5.23M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $5.23M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $5.23M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $5.23M 10-K · filed 2025-04-01 | |
| 2023-09-30 | $5.23M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $5.23M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $5.23M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $5.71M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $5.71M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $5.71M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $5.71M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $5.71M 10-K · filed 2023-03-29 | |
| 2021-10-23 | $901.00M 10-K · filed 2022-03-31 | $901.00K 10-Q · filed 2021-11-12 |
| 2021-09-30 | $1.39M 10-Q · filed 2021-11-12 | |
| 2021-08-10 | $4.45M 10-Q · filed 2022-05-13 | |
| 2021-06-30 | $901.00K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $901.00K 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $901.00K 10-K · filed 2023-03-29 | |
| 2020-10-23 | $901.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |